(Q40287113)

English

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

scientific article published on 16 September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia (English)

1 reference

Europe PubMed Central

19 September 2017

phase II clinical trial

0 references

author name string

Gonzalo Gomez-Abuin

1

1 reference

Europe PubMed Central

19 September 2017

Eric Winquist

2

1 reference

Europe PubMed Central

19 September 2017

Walter M Stadler

3

1 reference

Europe PubMed Central

19 September 2017

Greg Pond

4

1 reference

Europe PubMed Central

19 September 2017

Pamela Degendorfer

5

1 reference

Europe PubMed Central

19 September 2017

John Wright

6

1 reference

Europe PubMed Central

19 September 2017

Malcolm J Moore

7

1 reference

Europe PubMed Central

19 September 2017

publication date

16 September 2006

1 reference

Europe PubMed Central

19 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

19 September 2017

25

1 reference

Europe PubMed Central

19 September 2017

181-185

1 reference

Europe PubMed Central

19 September 2017

2

1 reference

Europe PubMed Central

19 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-006-9009-4

0 references

A Phase II study of oxaliplatin in urothelial cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-006-9009-4

21 January 2018

Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2005

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proteasome inhibitor PS-341 in cancer therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proteasome inhibition in cancer: development of PS-341.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16983508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-006-9009-4

1 reference

Europe PubMed Central

19 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40287113&oldid=1893475078"